For 2026, the landscape of Alzheimer’s treatment has officially shifted from a “symptom management” era to a “disease-modifying” era. For years, medications only temporarily masked memory loss and confusion. Today, we are seeing the first generation of therapies that target the underlying biological causes of the disease, specifically by clearing toxic proteins from the brain. This progress is fueled by advances in…










